Hemolens Diagnosticssp. z o.o.
Manufacture of medical and dental instruments and supplies
Overview
Hemolens Diagnostics is a company that has developed the Cardiolens FFR-CT Pro® technology, which provides a non-invasive diagnostic tool for assessing the severity of coronary artery disease. Their technology allows for detailed anatomical and functional evaluation of coronary arteries using methods such as coronary computed tomography angiography (CCTA) and continuous non-invasive blood pressure monitoring. This approach aims to reduce the need for invasive procedures in patients with intermediate-risk coronary artery disease.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
Cardiolens Viewer® with MDR certification – official handover by TÜV Rheinland
The official handover of the MDR certificate by the notified body TÜV Rheinland is an important milestone for us – confirming several years of work, many key design decisions, and the commitment of the entire Hemolens Diagnostics team. From certification to official handover In May 2026, we successfully completed the conformity assessment of Cardiolens Viewer® […]
How can technology give us more time? Hemolens Diagnostics at IT UNPLUGGED conference
Can technology give us more time? In healthcare, the answer is yes. More time for prevention, faster diagnosis, and more effective treatment. This idea was at the core of our participation in the IT UNPLUGGED conference in Lublin. IT UNPLUGGED – a meeting place for technology and business The IT UNPLUGGED event, organized by the […]
MDR Certified: Cardiolens Viewer® Clears a Rigorous EU Regulatory Threshold
We have successfully completed the MDR (EU) 2017/745 conformity assessment procedure for Cardiolens Viewer®. The assessment was conducted by TÜV Rheinland LGA Products GmbH, a notified body registered with the European Commission under number 0197. CE marking paves the way for the commercialization of our system in the European market. What MDR certification means in […]
Shaping the Future of Interventional Cardiology at EAPCI Summit 2026
On 19–20 February 2026, we participated in the EAPCI Summit 2026 held in Munich, Germany. This year’s edition was guided by the theme ‘Bringing together scientific rigour, multidisciplinary expertise, and training for the next generation.’ The two-day programme created a platform for in-depth discussions on access to care, the implementation of clinical standards, and the […]
The topic of AI and innovation dominated the 4th Conference of the Polish Cardiac Society (Wroclaw Department)
On February 20-21, 2026, the 4th Conference of the Polish Cardiac Society (Wroclaw Department) took place in Wrocław. The event gathered local physicians and leaders in cardiology and cardiac surgery, as well as specialists interested in the diagnosis and treatment of cardiovascular diseases. The two-day conference provided a platform for exchanging experiences and presenting the […]
Arm in arm: how in silico modelling and AI tackle the “grey zone” in coronary diagnostics
During the latest Avicenna Alliance webinar, our team presented how combining CCTA, in silico patient‑specific modelling, and AI may help address one of the most discussed areas in coronary diagnostics – the functional “grey zone” between clearly significant and clearly non‑significant lesions. In the presentation, CSO Ziemowit Ostrowski and co‑founder Andrzej Kosior described an approach […]
Industry
Bank accounts
Registered as a VAT taxpayer on 2016-01-26. Active
16 1050 0086 1000 0090 8691 2483- 59 1050 0086 1000 0090 8295 3333
- 10 1050 1025 1000 0090 8028 0101
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
7 public aid cases recorded, with a total value of $4,088,406.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Sep 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $16,968$16,968 | Prezes Zakładu Ubezpieczeń Społecznych | |
| Jun 24, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $16,982$16,982 | Prezes Zakładu Ubezpieczeń Społecznych | |
| Jun 24, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $16,652$16,652 | Prezes Zakładu Ubezpieczeń Społecznych |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2019-10-01 | Platforma chmurowa HEMOFLOW do nieinwazyjnej diagnostyki hemodynamicznej | $3.4M$3,373,609 | Program Operacyjny Inteligentny Rozwój |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
Declarations of will on behalf of the company are made by at least two members of the management board acting jointly, or by a member of the management board acting jointly with a commercial proxy.
Supervisory board
Ownership
| Owner | Shares | Stake |
|---|---|---|
Ms Galleon Gmbh | 778 | 100% |
Beneficial owners
| Person | Rights | |
|---|---|---|
Michał Andrzej Sołowow (64)  | Michał sołowow posiada 100% udziałów w ms galleon gmbh z siedzibą w wiedniu, która posiada 96,26% udziałów w spółce hemolens diagnostics spółka z ograniczoną odpowiedzialnością |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| EndolinkS.A. | $378,334.26 | endolink.pl | ||
| Stethomesp. z o.o. | $267,112.27 | stethome.com |
Change history
| Date | Event | |
|---|---|---|
| 2025-10-15 | Share capital change (364,500.00 PLN → 392,400.00 PLN) | |
| 2025-08-27 | Share capital change (327,800.00 PLN → 364,500.00 PLN) | |
| 2025-03-14 | Share capital change (318,500.00 PLN → 327,800.00 PLN) | |
| 2024-10-22 | Share capital change (248,750.00 PLN → 318,500.00 PLN) | |
| 2024-02-14 | Share capital change (169,000.00 PLN → 248,750.00 PLN) |
FAQ
Last updated: 2026-07-15